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Patient involvement in healthcare, in general, and in substance misuse in particular, has 
become a topic of paramount importance (Rutter et al., 2004). Patient involvement can be 
conceptualised as listening to the patients’ perspective and encouraging patients to take an 
active role in the care they are receiving. This approach is advocated by international authorities 
in health and social care such as the United Kingdom’s NICE, which recommends “person-
centred care” that takes into account the patient’s “needs, preferences and strengths” 
(Crawford, 2011). According to Orford (2008), the perspectives of patients in substance misuse 
treatment tend to be overlooked and their involvement with treatment is limited. However, the 
evidence on how patient involvement can be improved within the context of substance misuse 
programmes are scarce. Can we do something to shift this reality?  
 In healthcare, patients can become actively involved by collaborating with treatment 
outcome evaluation. In psychological treatments the commonest approach to this involves the 
use of standardised outcome measures (SOM), whose pre-set items, developed by research 
experts or professionals are rated by patients. The majority of SOM, both in psychological 
treatments (e.g., CORE-OM; Evans et al., 2000) and in substance misuse (e.g., TOP; Marsden 
et al., 2008), have had their psychometric properties extensively explored and their results are 
widely acknowledged as valid and reliable to evaluate treatment. However, due to their 
universal scope and applicability to both healthy populations and those with mental health 
conditions, SOM are unlikely to cover all the subjective concerns of patients, their priorities and 
their personal experiences in treatment.  
There is a different approach to evaluate treatment, which is based on patient-
generated, or individualised, outcome measures (PGOM). PGOM include items that are created 
by patients, resulting in personalised tailor-made scales that can be rated for severity, just like 
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SOM (Sales & Alves, 2012). There are several protocols to generate these personalised scales: 
for instance, the Personal Questionnaire (PQ; Elliott, Mack & Shapiro, 1999) is a semi-
structured interview where patients are asked to say which are “the main problems that led 
them to treatment” and then to rank order them by importance; or PSYCHLOPS (Ashworth et 
al., 2004), a self-report instrument where patients write down the two main problems they are 
currently experiencing and one thing that has become difficult to do because of those problems. 
When PGOM are used, the level of patient involvement with treatment evaluation increases 
substantially, which is important not only because patients and clinicians tend to appraise 
treatment differently, but also because most measurements are developed without direct input 
from patients (Crawford et al., 2011). Also, PGOM data is not fixed in time and allows patients to 
revise, delete obsolete problems or add new ones that might have arisen during therapy. 
PGOM are becoming increasingly popular in psychological treatments, given their 
advantages for outcome evaluation and clinical practice. As outcome measures, PGOM include 
patient case-specific information, as well as scores that quantify the distress caused by such 
problems, allowing a personalised evaluation of outcome (Sales & Alves, 2012); one of the 
properties of PGOM is greater sensitivity were found to be more sensitive to clinical change 
when compared with SOM; the trade-off is that PGOM have slightly lower levels of test-restest 
reliability and internal reliability (Lacasse et al, 1999). Nevertheless, the reliability levels of 
PGOM are satisfactory and this should not detract from their role as highly sensitive measures 
of change (Ashworth et al., 2008; Elliott et al., 2014); PGOM allow outcome measurement to 
take patient’s perspectives into account, making them feel more valued as individuals (Alves, 
Sales & Santos, 2014). As clinical tools, PGOM have been considered to be useful to 
complement diagnoses, case formulation and clinical-decision making (Sales et al., 2007; 
Sales, Alves, Evans & Elliott, 2014); and recently, patients reported satisfaction with the 
freedom that PGOM give them to focus on the topics which they prioritise during the evaluation 
process (Alves, Sales & Santos, 2014).  
But there are downsides to using PGOM. For instance, they have been considered 
time-consuming and are difficult to use with patients with certain impaired cognitive functions 
(e.g. memory). Moreover, PGOM hinder the comparison between patients (Sales et al., 2007; 
Soares et al., 2012), making it difficult to interpret their scores against population norms since 
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each ‘individualised’ measure is, in effect, offering a score for unique, individually defined items 
Hence, PGOM are not the “holy grail” of outcome assessment and cannot provide, alone, all the 
information that is needed to evaluate patients’ clinical situation.  
It has been recently suggested that PGOM should be added to standardised data for 
optimal results, in a strategy called personalised outcome measurement approach (Sales & 
Alves, 2012). In practice, this approach implies the combination of PGOM and SOM in the same 
evaluation protocol. Here is one example: to use, at the pre-treatment evaluation session, PQ or 
PSYCHLOPS, followed by CORE-OM. With SOM, therapists can quickly assess the patient’s 
level of distress based on clinical cut-offs; whilst PGOM identify the specific concerns of 
patients, giving more insight about how they perceive their own clinical situation. According to 
the characteristics of the service, personalised outcome protocols can be administered pre and 
post treatment; or on a session-to-session basis, to monitor the progress of patients throughout 
treatment. In such cases, as aforementioned, patients are able to update the contents contained 
in their PGOM, as many times as desired. 
The personalised outcome measurement approach has already been implemented in 
various mental health settings, from university-based counselling centres to day psychiatry units 
and also group therapy interventions, with positive results. These studies have been conducted 
as part of a practice-based research network, dedicated to personalised assessment, the IPHA 
Group (Sales, Alves, Evans & Elliott, 2014).  
As earlier stated, failing to include the patient’s perspective has been identified as one 
of ten areas which require a paradigm shift in psychological addiction treatment (Orford, 2008). 
If the personalised outcome measurement approach seems to work, on the one hand, and is, 
on the other, a potential strategy to increase patients’ involvement in treatment, could we extend 
it to this specific context? What would we gain from doing so? 
In substance misuse, improvements in mental health are among the most important 
treatment goals (Wanigaratne et al., 2005). However, psychological health tends to be 
evaluated with SOM such as the SF Health Survey (see Drug Treatment Outcomes Research 
Study, Jones et al., 2009 for an example), where the level of patient involvement is minimal, as 
previously explained. Also, as shown in previous reviews (e.g. Livingston et al., 2011), 
substance misuse disorders tend to be more stigmatized in comparison with other health 
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problems. This may not only act as a barrier for seeking healthcare, but also to poor and 
inadequate provision of care, potentially leading to early treatment drop-out and poor adherence 
(Livingston et al., 2011). 
From a clinical perspective, we believe that substance misuse treatment services could 
benefit from adopting the personalised measurement approach. First, the use of PGOM 
potentially allows clinicians to better understand how patients perceive their own situation. This 
is particularly relevant at the pre-treatment stage, because it helps clinicians preparing 
treatment plans that take the priorities of patients into account, instead of adopting “by-the-
book”, or protocol driven interventions. Also, in a population where drop-out rates are relatively 
high, to formally ask for patients’ help to evaluate their own situation might increase their 
motivation to continue with the treatment programme. 
 Second, adding PGOM to outcome measurement encourages patients to select and 
prioritise their own problems, regardless of whether these are drug-related or not. In this 
context, the tools used for screening and outcome measurement purposes focus primarily on 
drug use and drug-related risk behaviours (e.g. TOP; Marsden et al., 2008). However, patients 
may have other concerns that are perceived as of equal or greater importance than their drug 
use (e.g. recent death of a relative). As a female patient put it in focus group recently conducted 
in Portugal, “This questionnaire [PSYCHLOPS, a PGOM] helps people to think about all their 
difficulties in life. It is not just the alcohol” (Alves, Sales & Santos, 2014). Thus, even though 
PGOM do not substitute for diagnostic interviews or disorder-specific scales (e.g. Beck 
Depression Inventory) they may serve as flag alerts for clinical practice and further 
assessments.  
We also hope that using PGOM will contribute to diminishing, to some extent, the 
stigmatization of patients with substance misuse problems. It is not uncommon for these 
patients to be perceived as manipulative and untruthful, which may be related to reasons why 
their own perspectives tend to be overlooked. However, as illustrated in the previous paragraph, 
asking patients’ opinions about their own problem priorities enables health care workers to offer 
more holistic care (cf. above:‘its not just the alcohol) 
The personalised outcome assessment approach is also a potential tool to influence 
policies regarding treatment provision in this field. On the one hand, this measurement 
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approach provides an action plan, ultimately in the format of guidelines, for therapists to 
understand how to put the principle of “patient-centered” care into practice, as a means of 
improving quality of care in general. This is of importance at the time being, when health care 
budgets are increasingly constrained and funding decisions are dependent upon evidence of 
effectiveness judged both by professionals and patients.  
Second, personalised outcome measurement is a strategy that reconciles the existing  
approach to outcome assessment, with personalised questionnaires that serve not only as 
complementary outcome measures, but also as clinical tools that are useful to practice, and 
humanize the assessment procedure that is often regarded as impersonal ‘tick-box’ measures. 
As PGOM reflect the patient’s perspectives, we believe that they might provide insights 
about the problems which are most relevant to this population, so that we know, through the 
patient’s eyes, which areas should be more emphasized in drug misuse treatment programs. 
For instance, if the majority of patients report that unemployment is what concerns them the 
most, it might be necessary to revise the policies regarding social rehabilitation of patients in 
drug misuse treatment (e.g. increasing the number of partnerships between treatment centres 
and employment agencies). 
Also, adding PGOM to traditional outcome measures will lead to more comprehensive 
policies of treatment evaluation and delivery, for it includes the point of view of all the parties 
involved in healthcare, namely, the voice of patients who are likely to be unheard in substance 
misuse settings.  
Finally, as aforementioned, the use of tools to include the perspective of patients will, 
ultimately, contribute to a greater humanization of the substance misuse treatment system. All 
in all, from an ethical point of view, there is an imperative to enhance patient autonomy in 
patient care. By valuing what patients have to say – and involving them as actively as possible 
in the delivery of health care, we consider that this approach will maximize the potential benefit 
of treatment programmes.  
There are, however, several steps that need to be taken before this approach is fully 
acknowledged as feasible and reliable in substance misuse treatment. These include: 1) 
Piloting the personalised assessment approach in several international treatment agencies, to 
increase its robustness; 2) Discussing, with international drug monitoring agencies, the 
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appropriateness of developing and disseminating international guidelines for personalised 
assessment, to reduce the gap between treatment delivery and outcome assessment across 
countries; 3) Creating practice-based networks for drug treatment services to collaborate and 
share their experiences with personalised assessment, extending the cooperation between 
therapists, researchers and patients towards the improvement of healthcare (e.g. International 
Exchange Platform for Personalising Substance Misuse Treatment; Alves, Sales & Ashworth, 
2013). 
 To sum up, in this paper we have presented the personalised outcome measurement  
approach as a potential strategy to increase patient involvement with substance misuse 
treatment, an area in need of an urgent paradigm shift. Overall, this strategy potentially allows 
us to better accommodate the diversity and the idiosyncrasies of each patient that enters each 
consultation room. There is, however, the danger of becoming so individualized that it becomes 
difficult to have an overview about the population’s heterogeneity, rendering it  harder to plan 
services at a population level. Hopefully, the compromise that we propose between 
personalised and standardised measures is the ideal strategy to bridge these two worlds, but 
only further testing of where the balance lies will enable us to maximize the benefit from both 
approaches.  
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